ライフサイエンスコーパス: thyroid nodule

1 test for evaluating possible malignancy in a thyroid nodule.

2 .5 years) with a benign solitary or dominant thyroid nodule.

3 ncompass all newly evaluated patients with a thyroid nodule.

4 ken in all preadolescents (<13 years) with a thyroid nodule.

5 , neck palpation was not sensitive to detect thyroid nodules.

6 munostaining techniques in the evaluation of thyroid nodules.

7 he pathogenesis, diagnosis, and treatment of thyroid nodules.

8 eatment of hypothyroidism, and management of thyroid nodules.

9 detected in any of the patients with benign thyroid nodules.

10 e detected in two patients (10%) with benign thyroid nodules.

11 capable of detecting many small, nonpalpable thyroid nodules.

12 rs associated with the development of benign thyroid nodules.

13 ecommendations for follow-up of asymptomatic thyroid nodules.

14 hyperthyroidism in adults without goiter or thyroid nodules.

15 safe procedure for treatment of benign solid thyroid nodules.

16 ancy risk assessment of follicular-patterned thyroid nodules.

17 tic, sonographically or cytologically benign thyroid nodules.

18 idelines were used for work-up of incidental thyroid nodules.

19 inct definitive management for patients with thyroid nodules.

20 ostic testing in cytologically indeterminate thyroid nodules.

21 ing examples that have improved diagnosis of thyroid nodules.

22 ome mandatory while evaluating patients with thyroid nodules.

23 mas, but not in normal thyrocytes and benign thyroid nodules.

24 NAC) is the standard diagnostic modality for thyroid nodules.

25 ull-length hTERT were associated with benign thyroid nodules.

26 for planning initial clinical management of thyroid nodules.

27 r preoperative guidance in the management of thyroid nodules.

28 cal tool for the evaluation of patients with thyroid nodules.

29 ism or the development of actively secreting thyroid nodules.

30 uld serve as diagnostic markers of malignant thyroid nodules.

31 mits the discrimination of specific types of thyroid nodules.

32 diagnostic tool in the initial evaluation of thyroid nodules.

33 atients, and 4812 fine-needle aspirates from thyroid nodules 1 cm or larger that required evaluation.

34 f 288], P < .001) and multinodular goiter or thyroid nodule (40.7% [50 of 123] vs 29.2% [84 of 288],

35 on biopsy in the evaluation of patients with thyroid nodule and predicting disease aggressiveness.

36 Of 192 screened FAP patients, 72 (38%) had thyroid nodules and 5 (2.6%) had thyroid cancer.

37 gland disorders include benign and malignant thyroid nodules and diffuse thyroid disorders.

38 re excellent diagnostic markers of malignant thyroid nodules and may be used to improve the diagnosti

39 r imaging may aid exclusion of malignancy in thyroid nodules and molecular markers have great promise

40 The authors examined risk factors for benign thyroid nodules and their influence on radiation effects

41 e simple differentiation of solid and cystic thyroid nodules and their measurement.

42 el molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting

43 patient-oriented and tailored management of thyroid nodules and thyroid cancer.

44 mary search terms molecular, thyroid cancer, thyroid nodule, and gene expression classifier in search

45 in irradiated glands, the natural history of thyroid nodules, and the prevalence of occult cancer wer

46 reatment of hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer in children and adol

47 ence of one or more autonomously functioning thyroid nodules, and thyroiditis caused by inflammation,

48 renal cysts, liver hemangiomas, liver cysts, thyroid nodules, and uterine leiomyomas.

49 of malignancy in cytologically indeterminate thyroid nodules; and peripheral blood and fine-needle as

50 Thyroid nodules are common and most often benign.

51 Although thyroid nodules are common, few are malignant and requir

52 all cancers are present in the thyroid, yet thyroid nodules are found in 4 to 10% of the adult popul

53 Thyroid nodules are found in 4 to 7% of the population,

54 Because thyroid nodules are relatively common, the diagnostic di

55 Thyroid nodules are uncommon but malignant in as many as

56 toms of hypothyroidism, hyperthyroidism, and thyroid nodules, as well as the general approach to eval

57 As thyroid nodules become more prevalent clinicians are inc

58 r genetic alterations in diverse subtypes of thyroid nodules beyond PTC, including a variety of sampl

59 to discriminate between malignant and benign thyroid nodules, but nondiagnostic results remain a clin

60 The evaluation of thyroid nodules by fine-needle aspiration has been the s

61 of the patients (109 of 173) referred to the thyroid nodule clinic after abnormal results on thyroid

62 nts with concomitant suspicious or malignant thyroid nodules, coexisting hyperparathyroidism, and in

63 pathologic and histopathologic evaluation of thyroid nodules, confirming an inherent limitation of vi

64 cancer type, age at diagnosis, sex, and past thyroid nodule diagnosis.

65 After exclusion of nonavid thyroid nodules, diffuse (18)F-FDG uptake, known thyroid

66 it can be helpful in the routine analysis of thyroid nodules, especially in clinical settings with mo

67 Approximately 15 to 30% of thyroid nodules evaluated by means of fine-needle aspira

68 erapy does not seem to prevent recurrence of thyroid nodules except in patients with a history of rad

69 Mutation analysis in thyroid nodule fine needle aspiration biopsy has been ap

70 ith thyroid cancer, and molecular testing of thyroid nodule fine-needle aspiration (FNA) specimens ha

71 shouts of fine-needle aspiration biopsies of thyroid nodule from different patients.

72 Most solid, benign thyroid nodules grow.

73 Fine-needle aspiration biopsy of large thyroid nodules has a high false-negative rate and shoul

74 Fine-needle aspiration (FNA) of thyroid nodules has become the primary diagnostic tool i

75 tine calcitonin measurement in patients with thyroid nodules has been advocated for early detection o

76 Detection of asymptomatic thyroid nodules has increased.

77 the patients presenting with a single benign thyroid nodule have contralateral subclinical disease.

78 Patients whose thyroid nodules have indeterminate or suspicious cytolog

79 The natural history of benign thyroid nodules, however, is unclear.

80 perthyroidism (HR, 1.8; 95% CI, 1.2 to 2.8), thyroid nodules (HR, 6.3; 95% CI, 5.2 to 7.5), thyroid c

81 ised 68 consecutive patients with a solitary thyroid nodule in whom fine-needle aspiration showed a f

82 This review of thyroid nodules in children indicates that the incidence

83 The high prevalence of thyroid nodules in the adult population and the relative

84 may significantly enhance the evaluation of thyroid nodules in the future.

85 marker testing techniques for indeterminate thyroid nodules include gene expression classifier analy

86 used as an additional tool in the work-up of thyroid nodules instead of a single predictor of which l

87 Management of thyroid nodules is based on statistical data correlating

88 The incidence of malignant thyroid nodules is low and the prognosis is good.

89 rease in size with complete disappearance of thyroid nodules is not uncommon.

90 The gold standard evaluation for thyroid nodules is ultrasound-guided fine-needle aspirat

91 To discuss the problem of incidental thyroid nodules (ITN) detected on imaging; summarize the

92 borders and microcalcifications) within such thyroid nodules may have a stronger correlation for thyr

93 Changes in the diagnostic approach to thyroid nodules may have resulted in an increase in the

94 Thyroid nodules (n = 5349) that underwent US-guided FNA

95 The molecular work-up of thyroid nodules on fine needle aspiration (FNA) cytology

96 images showed alternative findings such as a thyroid nodule or metallic artifact.

97 idity and mortality, test accuracy to detect thyroid nodules or thyroid cancer, and harms resulting f

98 95% CI, 3.49-16.69), multinodular goiter or thyroid nodule (OR, 1.82; 95% CI, 1.01-3.28), and parath

99 enetic markers help raise the suspicion of a thyroid nodule possibly harboring an aggressive cancer;

100 iveness with which the diagnostic studies of thyroid nodules should be pursued.

101 Thyroid nodules should generally be studied with thyroid

102 Presence of thyroid nodules should prompt measurement of circulating

103 e aspiration biopsy identifies the childhood thyroid nodules that are at greatest risk for cancer.

104 conservative approach for most patients with thyroid nodules that are cytologically indeterminate on

105 tic, sonographically or cytologically benign thyroid nodules, the majority of nodules exhibited no si

106 ulation medians among the different types of thyroid nodules; the R software environment was used for

107 Thyroid nodules usually are an incidental finding on a r

108 Thyroid nodule volume, US structure, and Doppler pattern

109 Past thyroid nodule was consistently the strongest risk facto

110 In follow-up through 1991, benign thyroid nodules were diagnosed in 131 patients.

111 c findings, and other reports on nonpalpable thyroid nodules were included.

112 therapy for solitary and predominantly solid thyroid nodules were reviewed.

113 One hundred twenty-one thyroid nodules were sampled for biopsy in 109 patients.

114 and immunohistochemistry in the diagnosis of thyroid nodules, which may lead to a more rational appro

115 ove the clinical management of patients with thyroid nodules while reducing unnecessary surgery and s

116 For thyroid nodules whose cytology shows a follicular neopla

117 Thyroid nodules whose FNA is diagnosed as highly suspici

118 phy seems promising in identifying malignant thyroid nodules with acceptable accuracy, further studie

119 arkers, which may help to identify malignant thyroid nodules with greater specificity.

120 an discriminate between benign and malignant thyroid nodules with the necessary sensitivity and speci

121 ith basal serum calcitonin for patients with thyroid nodules would cost $11,793 per life-year saved (